Message Font: Serif | Sans-Serif
No. of Recommendations: 0

QLT's Sagging Sales
By Brian Lawler
January 22, 2007
My call on drug developer QLT (Nasdaq: QLTI) has been a classic case where being right about a company's prospects hasn't necessarily translated into being right about the direction of the stock's price (at least in the short run). Ever since I mentioned that it would be best for investors to stay away from QLT because of the oncoming competition from Genentech's (NYSE: DNA) Lucentis, shares have run up over 20%.........
Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.